IL33 rs1342326 gene variation is associated with allergic rhinitis at school age after infant bronchiolitis




Matti Korppi, Johanna Teräsjärvi, Eero Lauhkonen, Heini Huhtala, Kirsi Nuolivirta, Qiushui He

PublisherWILEY

2020

Acta Paediatrica

ACTA PAEDIATRICA

ACTA PAEDIATR

109

10

2112

2116

5

0803-5253

1651-2227

DOIhttps://doi.org/10.1111/apa.15175



Aim Interleukin (IL)-33, encoded by the IL33 gene, is associated with allergy and asthma. We evaluated IL33 rs1342326 polymorphism in relation to asthma, asthma medication and allergic rhinitis after infant bronchiolitis.Methods IL33 rs1342326 polymorphism was studied in children, who were hospitalised for bronchiolitis at age younger than 6 months and who were prospectively followed until 5-7 years (N = 141) and 11-13 years (N = 125) of ages.Results The presence of the wild AA vs variant AC or CC genotypes of the IL33 rs1342326 showed no significant associations with previous or current asthma at the mean ages of 6.4 or 11.7 years. However, 22.5% of children with the variant genotype used inhaled corticosteroids at the 5-7 years of visit (adjusted OR: 2.94, 95% CI: 1.04-8.33 vs those 8.9% with the wild genotype). The variant IL33 rs1342326 genotype was associated with allergic rhinitis at 6.4 years (adjusted OR: 2.17, 95% CI: 1.01-4.76) and 11.7 years (3.23, 1.18-9.09) of ages.Conclusion The frequent use of asthma control medication in 6.4-year-old children with IL33 rs1342326 polymorphism suggests that this variation may increase susceptibility to severe asthma at preschool age. The IL33 rs1342326 variant genotype was associated with a 3-fold risk of allergic rhinitis at school age.



Last updated on 2024-26-11 at 11:50